The Discovery, Alliances and Technologies department focuses on the progress of MorphoSys’s therapeutic programs with partnered and proprietary compounds. Thanks to their successful execution of projects with MorphoSys’s pharmaceutical and biotech partners, the Company is well-known in the industry as a reliable and high-quality collaboration partner. The department advances the development of new technologies in order to maintain technological leadership in the antibody sector. Just recently, lanthipeptides were added as a novel drug class to the portfolio. The team’s scientific knowledge and MorphoSys’s technologies are also the source of the in-house discovery of novel compounds.